Guidelines

Summary Report on Lianhua Qingwen Capsule/Granule for the Treatment of Influenza,Cold and Coronavirus Disease 2019 (COVID-19)

Lianhua Qingwen Capsule/Granule (hereinafter referred to as LHQW) is a new Chinese patent medicine (SFDA Approval No.: Z...

查看更多 →
Seventh Version Standard Therapy Published and National Award Winner Lianhua Qingwen Contributes to Prevention and Control of Epidemic Outbreak

On March 3, the Standard Therapy for Novel Coronavirus Pneumonia (Version VII, Tentative) was published by the National ...

查看更多 →
Lianhua Qingwen Recommended by the National Health Commission for Treatment during Medical Observation Period

The Standard Therapy for Novel Coronavirus Pneumonia (Version IV, Tentative) has been published by the National Health...

查看更多 →
Expert Consensus: Lianhua Qingwen Granules is Recommended for Children Infected by Novel Coronavirus during Medical Observation Period

Recently, the Expert Consensus Document on Diagnosis, Treatment and Prevention of Novel Coronavirus Infections in...

查看更多 →

    Address
    No.238 Tianshan street, East developing zone,Shijiazhuang,Hebei, China 
    Tel:
    +86-311-85901712

    Copyright:Shijiazhuang Yiling Pharmaceutical Co,Ltd. JI-ICP:12020237